OPKO Health/$OPK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About OPKO Health
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Ticker
$OPK
Sector
Primary listing
Employees
2,997
Headquarters
Website
OPKO Health Metrics
BasicAdvanced
$1.2B
-
-$0.26
1.19
-
Price and volume
Market cap
$1.2B
Beta
1.19
52-week high
$2.04
52-week low
$1.11
Average daily volume
2.2M
Financial strength
Current ratio
3.408
Quick ratio
2.205
Long term debt to equity
28.547
Total debt to equity
30.514
Interest coverage (TTM)
-2.28%
Profitability
EBITDA (TTM)
-172.847
Gross margin (TTM)
14.52%
Net profit margin (TTM)
-26.68%
Operating margin (TTM)
-40.29%
Effective tax rate (TTM)
-16.15%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-8.46%
Return on equity (TTM)
-13.16%
Valuation
Price to revenue (TTM)
1.566
Price to book
0.9
Price to tangible book (TTM)
18.95
Price to free cash flow (TTM)
-4.011
Free cash flow yield (TTM)
-24.93%
Free cash flow per share (TTM)
-0.374
Growth
Revenue change (TTM)
-7.31%
Earnings per share change (TTM)
-23.60%
3-year revenue growth (CAGR)
-22.50%
10-year revenue growth (CAGR)
18.88%
3-year earnings per share growth (CAGR)
-5.42%
10-year earnings per share growth (CAGR)
-8.04%
What the Analysts think about OPKO Health
Analyst ratings (Buy, Hold, Sell) for OPKO Health stock.
Bulls say / Bears say
OPKO partnered with Entera Bio to develop a once-daily obesity and metabolic disorder pill, targeting a market projected to reach $150 billion by 2030, which diversifies its pipeline into a high-growth therapeutic area (Reuters).
The Board authorized a $100 million increase to its share repurchase program—bringing total capacity to $200 million—showing management’s belief in OPKO’s undervaluation and commitment to returning capital to shareholders (Nasdaq).
Gross margin improved by 315 basis points to 31.5% in Q2 2025, demonstrating improved unit economics and cost control despite revenue challenges (Nasdaq).
Full-year revenue guidance was lowered to $640 million–$660 million from the prior outlook of $675 million–$685 million, highlighting soft top-line momentum and cautious management expectations (Nasdaq).
Net loss widened significantly to $148.4 million, or $0.19 per share, in Q2 2025—driven by a $91.7 million non-recurring expense—compared to a $10.3 million loss a year earlier, increasing concerns about shareholder value (OPKO Health).
Diagnostics segment revenues dropped 21.9% year-over-year to $101.1 million in Q2 2025 (from $129.4 million), reflecting lower clinical test volumes after BioReference asset sales and weighing on recovery in that segment (OPKO Health).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
OPKO Health Financial Performance
Revenues and expenses
OPKO Health Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for OPKO Health stock?
OPKO Health (OPK) has a market cap of $1.2B as of October 26, 2025.
What is the P/E ratio for OPKO Health stock?
The price to earnings (P/E) ratio for OPKO Health (OPK) stock is 0 as of October 26, 2025.
Does OPKO Health stock pay dividends?
No, OPKO Health (OPK) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next OPKO Health dividend payment date?
OPKO Health (OPK) stock does not pay dividends to its shareholders.
What is the beta indicator for OPKO Health?
OPKO Health (OPK) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.